查看文章

Objective: The constellation of elevated triglycerides and decreased high-density lipoprotein is recognised as a risk factor for CAD and constitutes the major dyslipidemia in type 2 diabetes. The highdensity lipoprotein associated paraoxonase activity can inhibit lowdensity lipoprotein oxidation and has an antiatherogenic effect. To determine the effect of gemfibrozil on the dyslipidemia and serum paraoxonase activity in patients with type 2 diabetes. Material and methods: Fifty-six type 2 diabetic patients with associated hypertriglyceridemia were involved. They were investigated for the effect of twice daily 600 mg of gemfibrozil on serum cholesterol, triglycerides, apolipoproteins, fibrinogen level, body mass index and glycated hemoglobin. Serum paraoxonase activity was measured spectrophotometrically.

Results: After three months, it was observed that under the effect of gemfibrozil, serum triglyceride level was significantly decreased (from median: 3.46 mmol/l quartiles: q1= 2.92 q3= 5.28 to median 2.20 mmol/l quartiles: q1= 1.79 q3= 3.65; p< 0.001) while protective high-density lipoprotein (from 1.02±0.22 mmol/l to 1.13±0.28 mmol/l; p= 0.05) and apolipoprotein A1 (from 1.56±0.33 g/l to 1.72±0.29; p< 0.01) levels were significantly increased. Serum paraoxonase activity was found to be significantly increased (from median: 100.2 U/l quartiles: q1= 60.1 q3= 152.7 to median 118.7 U/l quartiles: q1= 80.1 q3= 171.0; p< 0.001) after gemfibrozil treatment. The total cholesterol, low-density lipoprotein, apolipoprotein B, lipoprotein (a), glycated hemoglobin and fibrinogen levels were not significantly changed during the three-month treatment period. The …